Evidence map›Paper›PMID 42827555›Full record

ArticleFrontiers in immunology2026

Dysregulation of the cytotoxic-humoral axis and expansion of regulatory T cells in anti-TIF1γ- positive dermatomyositis.

Xiaoguang Cui, Kaihong Ye, Hong Wang, Junqiao Feng, Yameng Wei, Yali Kang, Nan Xu, Bo Cao, Fuqian Lei, Ke Du and 8 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Xiaoguang Cui *National-Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Kaihong Ye *Translational Research Institute of Henan Provincial People's Hospital and People's Hospital of Zhengzhou University, Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Hong Wang *Precision Medical Research Institute, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Junqiao FengNational-Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yameng WeiNational-Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yali KangNational-Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Nan XuDepartment of Clinical Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Bo CaoCore Research Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Fuqian LeiDepartment of Nephrology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ke DuNational-Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Kunyi WuCore Research Laboratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Xin YangDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Tian TianDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Shanshan WangDepartment of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China.
Wei WeiDepartment of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China.
Zhigang CaiDepartment of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China.
Xueyi LiDepartment of Rheumatology and Immunology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Ting LaNational-Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Dermatomyositis (DM), particularly the anti-TIF1γ‑positive subtype, is associated with a substantially elevated risk of malignancy. However, the peripheral immune landscape of this autoantibody-defined subset, especially in patients without concurrent cancer, remains incompletely understood. Methods: We performed single‑cell RNA sequencing of peripheral blood mononuclear cells (PBMCs) from five patients with anti‑TIF1γ‑positive DM (the subtype with the highest malignancy risk) and compared their profiles with those of two other DM subtypes: anti‑MDA5‑positive DM (intermediate malignancy risk) and anti‑synthetase syndrome (ASyS, low malignancy risk). Results: All three subtypes exhibited profound immune remodeling, characterized by reduced frequencies of cytotoxic lineage cells. Anti‑TIF1γ‑positive DM showed a compensatory shift toward humoral immunity, with increased B‑lineage cells, whereas classical monocyte elevation was specific to the anti‑MDA5‑positive DM and ASyS subtypes. Notably, anti‑TIF1γ‑positive DM was uniquely distinguished by an increased frequency of immunosuppressive regulatory T (Treg) cells, a finding validated by immunohistochemistry in patient skin tissue. Conclusion: These results delineate a peripheral immunological signature of anti‑TIF1γ‑positive DM, marked by compromised cytotoxic surveillance, aberrant humoral responses, and selective Treg enrichment. We hypothesize that this Treg elevation may contribute to an immunosuppressive milieu that favors malignancy, although this mechanism remains speculative and requires functional validation in prospective cohorts.

Indexed as

AutoantibodiesDermatomyositisT-Lymphocytes, RegulatoryTranscription FactorsAgedFemaleHumansMaleMiddle AgedT-Lymphocytes, CytotoxicAutoantibodiesTranscription FactorsTRIM33 protein, humananti-TIF1γ subtypedermatomyositismalignant risksingle‐cell analysisTreg

Identifiers

PMID42827555
PMCPMC13631053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.